COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says
Flu Now Posing New Challenge
Executive Summary
CEO of Chinese vaccine developer BravoVax shares views with Scrip on pandemic lessons learned and new approaches needed to move forward.
You may also be interested in...
Chinese Language Podcast: 出海新动向，数据出境，药监新政和后疫情的疫苗
The latest China biopharma trends, including Chinese biotech firms going overseas, post-COVID vaccine developments, new overseas data transfer standard contracts and developments at the Center for Drug Evaluation, are discussed in this Chinese-language podcast with Brian Yang in Beijing and Dexter Yan in Shanghai.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: ripples from SVB’s failure; Karuna’s schizophrenia win; big pharma remains open to partnering; ChatGPT comes to medical congresses; and China’s COVID vaccine lessons.
China Further Tightens Oversight Of Human Genetic Research
Although the latest implementing details classify many aspects of human genetic resource handling and transfer, foreign entities are severely restricted from developing gene and gene-editing therapies in China. Legal experts say the changes combined with data transfer and recent cybersecurity legislation pose additional challenges to life science companies operating in the country.